

## Invitation to presentation of BioInvent's Year-end report 2025

Lund, Sweden, February 26, 2026 – BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) invites investors, analysts, and the press to a presentation of the Year-end report 2025 on February 26 at 2:00 pm CET. The report will be published at 8:00 am CET today.

BioInvent's CEO Martin Welschhof will present the report together with CFO Stefan Ericsson. The presentation will be held in English.

When: Thursday February 26, 2026, at 2:00 pm CET

The webcast can be reached at <https://bioinvent.events.inderes.com/q4-report-2025>.

If you wish to ask questions and participate via telephone, please register at the link below. After registration you will be provided with a phone number and a conference ID to access the conference.

<https://events.inderes.com/bioinvent/q4-report-2025/dial-in>.

The conference call will be made available on the company website after the call.

### About BioInvent

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at [www.bioinvent.com](http://www.bioinvent.com).

For further information, please contact:

Cecilia Hofvander, VP Investor Relations

Phone: +46 (0)46 286 85 50

Email: [cecilia.hofvander@bioinvent.com](mailto:cecilia.hofvander@bioinvent.com)

BioInvent International AB (publ)

Co. Reg. No.: 556537-7263

Press Release  
26 February 2026 07:30:00 CET



---

Visiting address: Ideongatan 1  
Mailing address: 223 70 LUND  
Phone: +46 (0)46 286 85 50  
[www.bioinvent.com](http://www.bioinvent.com)

#### Attachments

---

[Invitation to presentation of BioInvent's Year-end report 2025](#)